Skip to Main Content

Advertisement

Skip Nav Destination
Current Issue
Volume 4,
Issue 22,
November 24, 2020

Featured Content


Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

Chimeric antigen receptor (CAR) T-cell therapy has proven to be an effective and remarkably durable treatment for some patients with relapsed and refractory diffuse large B-cell lymphoma. However, relapse is a persistent problem. Vercellino and colleagues evaluated predictive factors of early progression that may help guide which patients are most appropriate for this lifesaving but extremely expensive therapy.


A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score

Patients with relapsed/refractory non-Hodgkin lymphoma (NHL) have been shown to benefit from autologous transplantation. Still, criteria to determine prognosis would aid in better defining those patients who may benefit. Yhim and colleagues used a combination of the Deauville score from positron emission tomography scanning and clinical risk factors to stratify patients for outcome following autologous transplantation with intriguing findings.


Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice

Gene therapy for the treatment of hemophilia A is an emerging and exciting potential novel therapy. Wang and colleagues explored interesting approaches to enhance the therapeutic efficacy of this approach that may result in more efficacy in the clinic.


C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas

Chimeric antigen receptor (CAR) T-cell–based therapy directed against CD19 has proven to be effective for the treatment of diffuse large B-cell lymphoma. More recent studies using this approach for the treatment of patients with mantle cell lymphoma, which have recently achieved approval in several countries (including in the United States by the Food and Drug Administration), and follicular lymphoma have also been pursued and are the subject of the review by Jacobson and Maus. We hope you find it timely and informative.


Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

Chimeric antigen receptor (CAR) T cells has revolutionized the treatment of B-cell malignancies. Pasquini and colleagues report the impact of tisagenlecleucel in the treatment of children in the real-world setting, further demonstrating the efficacy of this treatment for children not enrolled in a clinical trial.


Whole transcriptome sequencing detects a large number of novel fusion transcripts in patients with AML and MDS

Molecular interrogation of a number of diseases, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), has yielded many novel gene fusions that have sometimes led to novel therapeutics. In the study by Stengel and colleagues, whole-transcriptome sequencing of a large number of AML and MDS samples revealed a number of novel fusion transcripts of biological and potential clinical importance.

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement

X